The present authors performed an open-label pilot review that administered psilocybin to fifteen procedure-resistant tobacco/nicotine-dependent people who smoke, in the context of cognitive behavioral therapy for smoking cessation [58]. Participants were administered ~0.29 mg/kg oral psilocybin with